664 related articles for article (PubMed ID: 27456662)
1. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
3. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
Guestini F; McNamara KM; Ishida T; Sasano H
Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targets of triple-negative breast cancer: a review.
Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N
Br J Pharmacol; 2015 Sep; 172(17):4228-37. PubMed ID: 26040571
[TBL] [Abstract][Full Text] [Related]
5. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
7. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
8. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
9. [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
Nowacka-Zawisza M; Krajewska WM
Postepy Hig Med Dosw (Online); 2013 Nov; 67():1090-7. PubMed ID: 24379250
[TBL] [Abstract][Full Text] [Related]
10. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
11. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
12. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
13. The functional role of Notch signaling in triple-negative breast cancer.
Speiser JJ; Erşahin C; Osipo C
Vitam Horm; 2013; 93():277-306. PubMed ID: 23810012
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer: molecular subtypes and new targets for therapy.
Lehmann BD; Pietenpol JA; Tan AR
Am Soc Clin Oncol Educ Book; 2015; ():e31-9. PubMed ID: 25993190
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
Lee A; Djamgoz MBA
Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Williams CB; Soloff AC; Ethier SP; Yeh ES
Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
[TBL] [Abstract][Full Text] [Related]
18. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.
Mai N; Abuhadra N; Jhaveri K
Clin Breast Cancer; 2023 Dec; 23(8):784-799. PubMed ID: 37336650
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
[TBL] [Abstract][Full Text] [Related]
20. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Sharma P
Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
